Danuglipron, also known as PF06882961, is another small oral molecule with GLP-1R agonist activity that has been proved in phase 1 clinical trials with T2DM subjects (NCT03538743) with successful results in relation to safety and tolerability and no clinically relevant electrocardiograms findings [101]. Here, GLP1R is linked to type 2 diabetes mellitus.